In December 2019 a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), formerly known as the 2019 novel coronavirus (2019-nCoV) was identified in Wuhan, China, causing a world-wide pandemic. Three coronaviruses, SARS-CoV, MERS-CoV, and SARS-CoV-2 have been identified as being a highly pathogenic for humans, and there is currently no effective antiviral treatment. Therefore, studies are focused on rapid development of vaccines and antiviral drugs to prevent and treat coronavirus infection. There are several potential strategies to pharmacologically fight against the disease (COVID-19), including vaccines, monoclonal antibodies, oligonucleotide-based therapies, peptides, interferon therapies, and small-molecule drugs (Dömling & Gao, 2020).SARS-CoV-2 3C-like proteinase (3CLpro) is the nonstructural protein number 5, also a cysteine protease, that is released from the virally encoded polyprotein by extensive proteolytic processing. The 3CLpro cleaves the C-terminal of the large replicase polyprotein 1ab (~790 kDa) at no fewer than 11 sites (Hegyi et al., 2002). Inhibiting the activity of this enzyme would block viral replication (Zhang et al., 2020). The functional importance of 3CLpro in the viral life cycle makes this protease an attractive target for the development of drugs directed against SARS and other coronavirus infections (Anand et al., 2003).
Source:Recombinant protein corresponding to full-length 2019-nCoV 3CLpro, part of the large replicase polyprotein 1ab (S3264-Q3569) from SARS-CoV-2 3C-Like Proteinase, fused to His-Tag at N-terminal, expressed in E. coli.
Molecular Weight:~35kD
Storage and Stability:Aliquot to avoid repeated freezing and thawing and store at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：200ug
Source Antigen：Recombinant, E. coli
Grade：Highly Purified
Purity：≥90%
Form：Supplied as a liquid in 50mM sodium phosphate, pH 7.5, 300mM sodium chloride, 200mM imidazole, 1mM DTT, 10% glycerol.
